Clinical trials
Follow clinical development from trial design and recruitment through results.
- Trial phase
- Status
- Readouts
Company intelligence / Profile preview
Welichem Biotech
Burnaby, British Columbia, Canadawelichem.com ↗
- Ownership
- Private
- Development stage
- Other
01
Overview
Welichem Biotech developed a pipeline of small molecule therapeutics for autoimmune/inflammatory diseases and cancer using its proprietary Symbiochem platform. Its lead candidate WBI-1001 showed promising safety and efficacy in Phase 1/2 trials for psoriasis and atopic dermatitis. The rights to WBI-1001 were acquired by Stiefel/GSK in 2012–2014 for global development outside China/Taiwan/Macau/Hong Kong. Other programs remained preclinical or early clinical.
- Therapeutic areas
- OncologyDermatologyImmunology
- Modalities
- Small molecule
- Industry
- Biotech
02
Partnerships
Stiefel/GSKShenzhen Celestial Pharmaceuticals Ltd.Beijing Wenfeng Tianji Pharmaceuticals Co. Ltd.
Beyond the preview
Go deeper on Welichem Biotech.
Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.
Licensing & deals
Explore licensing agreements, acquisitions, and the assets behind each deal.
- Partners
- Deal terms
- Milestones
Funding history
Trace financing activity and the investors behind a company’s development.
- Funding rounds
- Investors
- Capital raised
Competitive landscape
Compare peer pipelines by target, modality, and therapeutic area.
- Peer companies
- Targets
- Pipeline overlap
Technologies & patents
Explore technology platforms and the patent landscape around relevant assets.
- Platforms
- Patents
- Assignees
Research & analysis
Connect company news and source material to the questions you’re investigating.
- Company news
- Sources
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on Welichem Biotech.